Shilpa Medicare reports positive Phase 3 results for OERIS antiemetic injection

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

SHILPAMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.3%Reaction day

₹368.10

prior close

₹383.90

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.4%+4.7% vs market

Pharmaceuticals peers, median of 155sector-0.1%+4.4% vs sector

On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 4.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.3

10m

-1.8

15m

-1.4

30m

-0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.3-0.4+4.7-0.1+4.4

Next day

+7.2-0.6+7.8-0.8+8.0

+8.4+0.3+8.1+0.2+8.2

+5.7+0.2+5.4-0.0+5.7

+2.7+0.1+2.6+0.2+2.5

+2.4+0.7+1.7+0.3+2.1

-1.4-0.3-1.1-0.7-0.7

15d

-5.5-2.0-3.5-1.4-4.1

-10.4-5.7-4.7-3.6-6.7

-19.8-7.8-11.9-6.2-13.5

-7.9-4.6-3.3-6.7-1.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shilpa Medicare announced positive Phase 3 results for OERIS, a once-weekly ondansetron injection for chemotherapy-induced nausea and vomiting (CINV). In a 240-patient trial across Indian oncology centers, OERIS showed 89 percent complete response versus 82 percent for standard ondansetron, with no serious adverse events. OERIS addresses both acute and delayed CINV for up to five days in a single dose. Company plans filing with DCGI and US registration via 505(b)(2) pathway.

Likely market impact

Strong Phase 3 outcome moves OERIS closer to regulatory filing, opening a USD 375 million global CINV market opportunity.